Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Smoldering Multiple Myeloma, B- PRISM Study
- Age >= 18 years
- Must meet criteria of high-risk smoldering MM as described with one of the below criteria: * Bone marrow clonal plasma cells >= 10% and any one or more of the following: ** Serum M protein >= 3.0 gm/dL ** Immunoparesis with reduction of two uninvolved immunoglobulin isotypes ** Serum involved/uninvolved free light chain ratio >= 8 (but less than 100) *** Free light chain smoldering myeloma patients are not excluded ** Progressive increase in M protein level (Evolving type of smoldering multiple myeloma [SMM]) *** Increase in serum monoclonal protein by >= 10% on two successive evaluations within a 6-month period ** Bone marrow clonal plasma cells 50-60% ** Abnormal plasma cell immunophenotype (>= 95% of bone marrow plasma cells are clonal) and reduction of one or more uninvolved immunoglobulin isotypes ** High risk fluorescence in situ hybridization (FISH) defined as any one or several of the following: t(4;14), t(14;16), t(14;20), del 17p or 1q gain ** Magnetic resonance imaging (MRI) with diffuse abnormalities or 1 focal lesion (>= 5 mm) ** Positron emission tomography (PET)-computed tomography (CT) with one focal lesion (>= 5 mm) with increased uptake without underlying osteolytic bone destruction * OR High-risk per International Myeloma Working Group (IMWG)/Mayo 2018 “20-2-20” Criteria (at least 2 of the following) ** Bone marrow plasmacytosis >= 20% ** >= 2 g/dl M protein ** >= 20 involved: uninvolved serum free light chain ratio
- No evidence of Calcium elevation, Renal dysfunction, Anemia, Bone disease (CRAB) criteria* or new criteria of active MM which including the following: * Increased calcium levels: Corrected serum calcium > 0.25 mmol/L (> 1 mg/dL) above the upper limit of normal or > 2.75 mmol/L (> 11 mg/dL); * Renal insufficiency (attributable to myeloma); * Anemia (hemoglobin [Hgb] 2g/dL below the lower limit of normal or < 10 g/dL); * Bone lesions (lytic lesions or generalized osteoporosis with compression fractures) * No evidence of the following new criteria for active MM including the following: ** Bone marrow plasma cells > 60% ** Serum involved/uninvolved FLC ratio >= 100 ** MRI with more than one focal lesion * Participants with CRAB criteria that are attributable to conditions other than the disease under study may be eligible after discussion with the sponsor investigator
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2
- Absolute neutrophil count (ANC) >=1000/uL (obtained =< 28 days prior to registration)
- Platelet (PLT) >= 50,000/uL (obtained =< 28 days prior to registration)
- Total bilirubin =< 2.0 mg/dL (If total is elevated check direct and if normal patient is eligible.) (obtained =< 28 days prior to registration)
- Aspartate aminotransferase (AST) =< 3 x institutional upper limit of normal (ULN) (obtained =< 28 days prior to registration)
- Alanine aminotransferase (ALT) =< 3 x institutional upper limit of normal (ULN) (obtained =< 28 days prior to registration)
- Estimated creatinine clearance >= 60 mL/min or a creatinine =< 2.2 mg/dL (obtained =< 28 days prior to registration)
- Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care
- Females of childbearing potential must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 – 14 days and again within 24 hours prior to prescribing lenalidomide for cycle 1 (prescriptions must be filled within 7 days as required by Revlimid REMS) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide * A female of childbearing potential is a sexually mature female who: ** Has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or ** Has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time during the preceding 24 consecutive months
- All study participants must be registered into the mandatory Revlimid REMS program and be willing and able to comply with the requirements of the REMS program
- Females of child-bearing potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
- Men must agree to use a latex condom during sexual contact with a female of childbearing potential even if they have had a successful vasectomy
- Detectable clonality sequence by next generation sequencing using clonoSEQ assay to allow for minimal residual disease measurement
- Ability to understand and the willingness to sign a written informed consent
- Symptomatic multiple myeloma or any evidence of CRAB criteria, including presence of myeloma defining events (MDE). Any prior therapy for active Myeloma should also be excluded. Prior therapy for smoldering myeloma is not an exclusion criterion. Bisphosphonates are not excluded
- Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational. Prior therapy with bisphosphonate is allowed. Prior radiation therapy to a solitary plasmacytoma is allowed. Prior clinical trials or therapy for smoldering MM or monoclonal gammopathy of undetermined significance (MGUS) are allowed but should be discussed with the principal investigator
- Serious medical or psychiatric illness likely to interfere with participation in this clinical study
- Diagnosed or treated for another malignancy within 2 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in-situ malignancy, or low-risk prostate cancer after curative therapy
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant or nursing women will be excluded from the study because lenalidomide is an agent with the potential for teratogenic or abortifacient effects
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to daratumumab, bortezomib, lenalidomide, or hyaluronidase
- Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) or SARS-CoV-2 (coronavirus disease 2019 [COVID-19]) * Patients who are seropositive because of hepatitis B virus vaccine are eligible. * Patients who are positive for SARS-COV-2 antibody, HIV1 and 2 antibody, hepatitis B core antibody or hepatitis B surface antigen must have a negative polymerase chain reaction (PCR) result before enrollment. Those who are PCR positive will be excluded
- Subject has known chronic obstructive pulmonary disease (COPD) or severe, persistent asthma with a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal * Note that pulmonary function test (PFT)/FEV1 testing is required at screening for patients suspected of having COPD or severe, persistent asthma or are suspected of having those conditions or other respiratory impairment
I. To determine the proportion of high-risk smoldering multiple myeloma patients who are minimal residual disease (MRD) negative at 2 years after receiving daratumumab, bortezomib, lenalidomide and dexamethasone combination therapy.
I. To assess rate of MRD negativity at 6 months, 1 year and durable MRD negativity rate beyond 1 year.
II. To assess progression free survival at 2 years.
III. To assess the response rates.
IV. To assess time to progression.
V. To assess duration of response.
VI. To assess overall survival.
VII. To assess safety of the combination.
I. To assess mass spectrometry quantification of M-protein.
II. To examine molecular evolution of the tumor cells.
III. To determine the role of immune cells in the progression of smoldering multiple myeloma (MM).
Patients receive daratumumab subcutaneously (SC) on 1, 8, 15, and 22, bortezomib SC on days 1, 8, and 15, lenalidomide orally (PO) once daily (QD) on days 1-21, and dexamethasone PO QD on days 1, 8, 15, and 22 of cycles 1-2. Patients receive daratumumab SC on days 1 and 15, bortezomib SC on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO QD on days 1, 8, and 15 of cycles 3-6. Patients receive daratumumab SC on day 1, bortezomib SC on days 1 and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO QD on days 1 and 15 of cycles 7-24. Treatments repeat every 28 days for 24 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3-6 months for up to 3 years.
Trial Phase Phase II
Trial Type Treatment
Dana-Farber Harvard Cancer Center
- Primary ID 21-007
- Secondary IDs NCI-2021-02158
- Clinicaltrials.gov ID NCT04775550